Bridge Pharmaceuticals Dedicates Its Preclinical Drug Development
Laboratory in Beijing

Bridge Pharmaceuticals Inc., Together With WI Harper and Vital
Bridge, Announce the Dedication of Its State-of-the-Art Preclinical
Drug Development Laboratory at Zhongguancun Life Science Park in
Beijing

Today, Bridge Pharmaceuticals had the dedication ceremony for its
recently completed Bridge Zhongguancun Preclinical Drug Development
Laboratory I. In attendance at the ceremony were: San Francisco
Mayor Gavin Newsom; Deputy Mayor Beijing Municipal Office Hao Lu;
Beijing Deputy Mayor Bo-Yuan Fan; US Embassy Senior Commercial
Officer Craig Allen; Former Beijing Deputy Mayor Zhao-Guang Hu;
Director of Beijing Municipal Industrial Development Bureau Lian-
Yuan Cheng; Director of Beijing Municipal Science Technology Office
Hai Feng; and Former San Francisco Mayor Frank Jordon.

This 7,800 square meter facility puts Bridge at the forefront of
preclinical outsourcing to China and will be the first and only US
level GLP and AAALAC designed facility in China. The Zhongguancun
facility will house primates, rodents, canines, rabbits. Services
will include: FDA compliant GLP toxicology, pharmacology, predictive
PK/ADMET, safety pharmacology, formulation and other services.
Through its Vital Bridge joint venture, Bridge has expert local
partners in China that provide animal supplies from the largest and
only US-franchised (Charles River and Marshall Farms) quality animal
breeding facilities in China.

For Bridge, the opening of this facility marks the next phase in
outsourcing preclinical drug development to Asia. By controlling its
own facility in China, Bridge will have the capacity and expertise
to provide FDA compliant preclinical drug development services to
pharmaceutical and biotech companies throughout the world. This new
facility positions Bridge as the leading preclinical CRO in China
targeting US and EU biopharmaceutical companies.

"The San Francisco Bay Area is the birthplace of biotech and has
remained the worldwide leader in life sciences innovation.
Escalation of the price of drugs, as evidenced by California's
recent ballot initiative, is an increasing hardship and concern,"
said San Francisco Mayor Gavin Newsom. "By combining the technical
resources and innovation of both the San Francisco Bay Area and
Beijing's life sciences community, this state-of-the-art facility
represents the next wave of global cooperation and evolution of life
sciences development. Bridge, and companies like Bridge, will allow
San Francisco to remain competitive in the life sciences, and cost
effectively develop more drugs, for smaller markets, in the new era
of personalized molecular medicine. We are pleased to see that a Bay
Area company, Bridge Pharmaceuticals, is taking the lead in this
exciting global evolution of the very best of the east and west."

Founded in 2004, Bridge Pharmaceuticals, Inc. was spun-out of SRI
International (formerly Stanford Research Institute) to develop
preclinical service and drug development capabilities through
leverage of the Asian market. To date, Bridge has been
subcontracting work through laboratories in China and Taiwan
(Beijing, Shanghai, Chengdu, Taipei and elsewhere). Bridge is the
first company to successfully use all China preclinical and CMC data
for successful filing of IND's with the US FDA and did so twice this
year.

"Two years ago, we asked a simple question -- why can't one perform
FDA compliant drug development in China for US clients at a fraction
of the normal price?" CEO and President, Glenn Rice, Ph.D.
said. "China has the world's leading primate animal supply, highly
qualified technical staff, good English language skills and
excellent worker productivity, in addition to significant cost
savings. Bridge builds on China's strengths by adding: SOP sourcing
from the US, world class facilities in the leading life sciences
park in China, FDA compliance, AAALAC level animal welfare, real
time data monitoring, combined with a US headquartered company that
envisions flexible partnerships.

"Of course doing business in China takes a lot of local know how,
experienced investment strategy and government support. We are
combining the best of east and west and we are confident it is going
to revolutionize preclinical drug development worldwide. We are
indebted to our investors, particularly Peter Liu, Chairman of the
WI Harper Group who has guided our business from day one in China."

About Bridge Pharmaceuticals

Bridge Pharmaceuticals is a US-headquartered, SRI International spin-
off company focused on providing cost effective, FDA compliant drug
development services in Asia for US, EU and Asian based clients.
Bridge has also formed BridgeNet, an unprecedented network of pre-
screened chemical and manufacturing service providers in China and
Taiwan, which provides western clients with a single point of
contact to access highly qualified and cost effective drug
development services in Asia. Bridge provides complete end-to-end
drug development expertise including US IND submissions. Bridge
focuses its development work in Taiwan and China. For more
information, visit www.BridgePharmaceuticals.com or call 650-859-
3853.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech